{"filings":[{"id":1251796,"accession_number":"0001104659-26-077354","cik":1813814,"company_name":"Definium Therapeutics, Inc.","ticker":"DFTX","form_type":"8-K","filed_at":"2026-06-24T21:14:45+00:00","items":["1.01","8.01","9.01"],"status":"ready","headline":"Definium Therapeutics prices $805M public offering of 20.6M shares at $34 each, upsized from $700M","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Offering of 20,588,236 common shares at $34.00 per share, with full exercise of underwriters' 30-day option for additional 3,088,235 shares.","Gross proceeds ~$805M; net proceeds ~$758M after underwriting discounts and expenses.","Proceeds to fund R&D, commercialization preparation for DT120 ODT if approved, and working capital.","Underwriters: J.P. Morgan, Jefferies, Leerink, BofA, Evercore ISI, Stifel, Oppenheimer, LifeSci.","Expected close June 25, 2026; 60-day lock-up for directors, officers, and company."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.9,"calibrated_materiality_score":0.9,"market_cap_usd":2477451958.306547,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":1177278,"accession_number":"0001104659-26-076091","cik":1813814,"company_name":"Definium Therapeutics, Inc.","ticker":"DFTX","form_type":"8-K","filed_at":"2026-06-22T12:01:50+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"Definium Therapeutics reports positive Phase 3 results for DT120 ODT in major depressive disorder","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Study met primary endpoint with 8.1-point MADRS placebo-adjusted improvement at Week 6 (p<0.0001)","7.3-point MADRS placebo-adjusted improvement at Week 12 (p<0.0001), showing durability","DT120 ODT was generally well tolerated; no serious adverse events or suicidality signal","Company to host webcast at 8:00 a.m. EDT on June 22, 2026 to discuss results"],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.9,"calibrated_materiality_score":0.9,"market_cap_usd":2477451958.306547,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":1028238,"accession_number":"0001193125-26-269549","cik":1813814,"company_name":"Definium Therapeutics, Inc.","ticker":"DFTX","form_type":"8-K","filed_at":"2026-06-12T20:30:17+00:00","items":["5.02","5.07","9.01"],"status":"ready","headline":"Definium shareholders approve 5M share increase in equity plan, re-elect directors","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Shareholders approved amendment to 2025 Equity Incentive Plan, increasing shares by 5,000,000 to 9,500,000 total.","All seven director nominees elected: Barrow, Bruhn, Crystal, Gryska, Krebs, Vallone, Adsett.","Appointment of KPMG LLP as independent auditor approved for fiscal year until 2027 annual meeting.","Quorum of 78,673,592 shares (approx. 72% of outstanding) was present at the June 11, 2026 meeting.","Equity Plan Amendment effective immediately upon shareholder approval at the Annual Meeting."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":2477451958.306547,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":508636,"accession_number":"0001193125-26-229657","cik":1813814,"company_name":"Definium Therapeutics, Inc.","ticker":"DFTX","form_type":"8-K","filed_at":"2026-05-19T11:30:21+00:00","items":["8.01","9.01"],"status":"ready","headline":"Definium Therapeutics posts updated corporate presentation; no specifics disclosed","summary_kind":"llm","event_type":"other","confidence":"low","bullets":["Updated corporate presentation posted to company website on May 19, 2026.","No financial results, guidance changes, or pipeline updates can be extracted from the filed exhibit.","Confidence is low because the presentation content beyond the cover page was not provided.","Ticker DFTX; event is routine with no directional signal."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":2477451958.306547,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":22845,"accession_number":"0001193125-26-218251","cik":1813814,"company_name":"Definium Therapeutics, Inc.","ticker":"DFTX","form_type":"8-K","filed_at":"2026-05-12T12:15:16+00:00","items":["8.01","9.01"],"status":"ready","headline":"Definium doses first patient in Phase 3 Ascend study of DT120 ODT for MDD; topline data expected 2027","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["First patient dosed in Ascend, second Phase 3 pivotal study of DT120 ODT (lysergide tartrate) for major depressive disorder.","Primary endpoint: change from baseline in MADRS score at Week 6 for DT120 ODT 100 µg vs placebo.","Study to enroll 175 participants in the U.S.; topline data from 12-week double-blind period anticipated in 2027.","Ascend design aligns with Emerge Phase 3 and GAD trials; includes 40-week open-label extension and 2:1:2 randomization.","50 µg DT120 arm included to confound dose condition awareness and address functional unblinding concerns."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":2477451958.306547,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":95698,"accession_number":"0001193125-26-211929","cik":1813814,"company_name":"Definium Therapeutics, Inc.","ticker":"DFTX","form_type":"8-K","filed_at":"2026-05-07T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Definium Therapeutics Q1 2026: cash $373.4M; three Phase 3 readouts for DT120 ODT expected in coming months","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Cash and investments $373.4M as of March 31, 2026; expected to fund operations into 2028.","R&D expenses $41.5M (up $18.1M YoY) driven by DT120 ODT program costs; G&A $17.7M (up $8.9M).","Three Phase 3 topline data readouts for DT120 ODT anticipated: Emerge (MDD) late Q2 2026, Voyage (GAD) early Q3, Panorama (GAD) late Q3.","DT120 ODT program expanded into PTSD; Phase 3 Haven study expected to initiate in 2027 with ~200 patients.","Ascend (MDD) trial first patient dosing expected Q2 2026; enrollment complete in Emerge and Voyage."],"consensus_eps_estimate":-0.502,"consensus_eps_actual":-0.71,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2026-Q1","consensus_source":"xbrl+finnhub","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":2477451958.306547,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":95697,"accession_number":"0001193125-26-170509","cik":1813814,"company_name":"Definium Therapeutics, Inc.","ticker":"DFTX","form_type":"8-K","filed_at":"2026-04-22T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Definium provides DT120 ODT clinical updates; MDD/GAD readouts in 2H 2026, expansion into PTSD","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["MDD Emerge trial topline data on track for late 2Q 2026; 149 participants randomized 1:1 to DT120 100 µg or placebo.","GAD Voyage trial fully enrolled at 214 participants; topline data expected early 3Q 2026.","GAD Panorama sample size re-estimated to 200; screening closed, topline readout now late 3Q 2026 (previously 2H 2026).","PTSD program expanded with Phase 3 Haven study (~200 pts) initiating in 2027; primary endpoint CAPS-5 at Week 8.","Company presented commercial strategy for DT120 ODT as a potential multi-billion-dollar opportunity."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":2477451958.306547,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":108938,"accession_number":"0001193125-26-076612","cik":1813814,"company_name":"Definium Therapeutics, Inc.","ticker":"DFTX","form_type":"8-K","filed_at":"2026-02-26T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Definium Therapeutics FY2025 cash $411.6M; Phase 3 MDD trial fully enrolled, topline late Q2 2026","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Cash, cash equivalents and investments of $411.6M as of Dec 31, 2025, up from $273.7M in 2024; expected to fund operations into 2028.","Phase 3 MDD trial Emerge fully enrolled (149 patients); topline data anticipated late 2Q 2026.","Phase 3 GAD trial Voyage ~80% enrolled, no sample size increase needed; topline early 3Q 2026.","Phase 3 GAD trial Panorama enrollment on track; topline 2H 2026. Sample size re-estimation update on April 22 Investor Day.","Completed $259M equity financing in Q4 2025; appointed new CFO, CCO, and board member Roger Adsett."],"consensus_eps_estimate":-0.4974,"consensus_eps_actual":-2.06,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2025-FY","consensus_source":"xbrl+finnhub","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":2477451958.306547,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":108937,"accession_number":"0001193125-26-028186","cik":1813814,"company_name":"Definium Therapeutics, Inc.","ticker":"DFTX","form_type":"8-K","filed_at":"2026-01-29T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Definium Therapeutics appoints Roger Adsett to board, expanding to 7 directors","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Board increased from 6 to 7 directors; Adsett appointed effective Jan 29, 2026.","Adsett receives $40,000 annual cash retainer paid quarterly in arrears.","Granted option for 50,000 common shares; vests 1/3 on first anniversary, then monthly.","Not assigned to any board committees initially."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":2477451958.306547,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":108939,"accession_number":"0001193125-26-009854","cik":1813814,"company_name":"Definium Therapeutics, Inc.","ticker":"DFTX","form_type":"8-K","filed_at":"2026-01-12T23:59:59+00:00","items":["2.02","5.03","8.01","9.01"],"status":"ready","headline":"MindMed rebrands to Definium Therapeutics; $412M cash; three Phase 3 readouts in 2026","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Preliminary cash and investments ~$412M as of Dec 31, 2025.","Name changed to Definium Therapeutics; new ticker DFTX effective Jan 13.","Three Phase 3 readouts for DT120 ODT (GAD/MDD) in 2026: Voyage (2Q), Panorama (2H), Emerge (mid-year).","Analyst Day in 2Q 2026 to highlight pipeline and path to commercialization.","DT402 Phase 2a for autism spectrum disorder dosed first patient; initial data in 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":2477451958.306547,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":125393,"accession_number":"0001193125-25-269548","cik":1813814,"company_name":"Definium Therapeutics, Inc.","ticker":"DFTX","form_type":"8-K","filed_at":"2025-11-06T23:59:59+00:00","items":["2.02","8.01","9.01"],"status":"ready","headline":"MindMed Q3 cash $209M, raises $242.8M; MM120 Phase 3 GAD/MDD readouts on track for 2026","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Cash, cash equivalents and investments of $209.1M at Sept 30, 2025; net proceeds of $242.8M from Oct 31 offering extend runway into 2028.","R&D expenses $31.0M in Q3 2025 vs $17.2M in Q3 2024, driven by MM120 program costs.","Phase 3 Voyage (GAD) topline data expected 1H 2026; Panorama (GAD) 2H 2026.","Phase 3 Emerge (MDD) topline data accelerated to mid-2026 (from 2H 2026); Ascend (MDD) to initiate mid-2026.","Phase 2a of MM402 for ASD to start Q4 2025; MM120 Phase 2b published in JAMA."],"consensus_eps_estimate":-0.5113,"consensus_eps_actual":-1.56,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2025-Q3","consensus_source":"xbrl+finnhub","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":2477451958.306547,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":125392,"accession_number":"0001104659-25-104696","cik":1813814,"company_name":"Definium Therapeutics, Inc.","ticker":"DFTX","form_type":"8-K","filed_at":"2025-10-31T23:59:59+00:00","items":["1.01","8.01","9.01"],"status":"ready","headline":"MindMed prices $225M public offering of 18.375M shares at $12.25/sh; upsize to $258.9M after full over-allotment","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Issued 18,375,000 common shares at $12.25 per share; underwriters exercised option for additional 2,756,250 shares.","Gross proceeds of $258.9M; net proceeds of $242.8M after underwriting discounts and estimated expenses.","Offering closed October 31, 2025; Jefferies, Leerink Partners, Evercore ISI as joint bookrunners.","Net proceeds to fund R&D of product candidates, working capital, and potential complementary acquisitions.","Directors and executive officers subject to 90-day lock-up on share sales without consent."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":2477451958.306547,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":125391,"accession_number":"0001104659-25-103726","cik":1813814,"company_name":"Definium Therapeutics, Inc.","ticker":"DFTX","form_type":"8-K","filed_at":"2025-10-29T23:59:59+00:00","items":["2.02","8.01","9.01"],"status":"ready","headline":"MindMed reports preliminary cash ~$209.1M as of Sep 30, 2025","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Preliminary cash, cash equivalents and investments total approximately $209.1M as of September 30, 2025.","Data is unaudited and subject to KPMG review; may differ from final Q3 figures.","Filed a prospectus supplement and posted an updated corporate presentation on October 29, 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":2477451958.306547,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":142127,"accession_number":"0000950170-25-112973","cik":1813814,"company_name":"Definium Therapeutics, Inc.","ticker":"DFTX","form_type":"8-K","filed_at":"2025-09-04T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"MindMed publishes Phase 2b results for MM120 (LSD) in GAD in JAMA; 100 µg dose meets endpoints","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["MM120 100 µg showed 7.6-point greater HAM-A reduction vs placebo at Week 4 (p<0.0004, d=0.88); 65% response rate, 48% remission at Week 12.","Phase 2b study in 198 adults with moderate-to-severe GAD met primary and key secondary endpoints; dose-response demonstrated.","MM120 was well-tolerated; adverse events mild-to-moderate, transient, consistent with LSD effects.","FDA granted Breakthrough Therapy Designation for MM120 in GAD; Phase 3 trials (Voyage, Panorama, Emerge) enrolling."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":2477451958.306547,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":142126,"accession_number":"0000950170-25-100902","cik":1813814,"company_name":"Definium Therapeutics, Inc.","ticker":"DFTX","form_type":"8-K","filed_at":"2025-07-31T23:59:59+00:00","items":["2.02","8.01","9.01"],"status":"ready","headline":"MindMed Q2 2025 net loss widens to $42.7M; cash $237.9M; Phase 3 trials on track","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $42.7M in Q2 2025 vs $5.9M in Q2 2024, driven by higher R&D and warrant fair value changes.","Cash, cash equivalents and investments totaled $237.9M as of June 30, 2025, sufficient into 2027.","R&D expenses rose to $29.8M from $14.6M YoY, primarily due to MM120 ODT program advancement.","Phase 3 Voyage (GAD) topline data expected 1H 2026; Panorama (GAD) and Emerge (MDD) data in 2H 2026.","Appointed Brandi L. Roberts as CFO, bringing over 25 years of life sciences financial leadership."],"consensus_eps_estimate":-0.3717,"consensus_eps_actual":-0.81,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2025-Q2","consensus_source":"xbrl+finnhub","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":2477451958.306547,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":160101,"accession_number":"0000950170-25-086830","cik":1813814,"company_name":"Definium Therapeutics, Inc.","ticker":"DFTX","form_type":"8-K","filed_at":"2025-06-16T23:59:59+00:00","items":["5.02","5.07","9.01"],"status":"ready","headline":"MindMed shareholders approve 2025 Equity Incentive Plan authorizing 4.5M new shares","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Plan replaces prior stock option and restricted share unit plans; 4,500,000 common shares reserved.","All six director nominees (Robert Barrow, Dr. Suzanne Bruhn, Dr. Roger Crystal, David Gryska, Andreas Krebs, Carol A. Vallone) elected with >99% votes for each.","KPMG LLP ratified as independent auditor for the next year (42,583,160 for, 267,331 withheld).","Plan approved by shareholders: 28,452,155 for, 581,911 against, 110,688 abstain, 13,705,737 broker non-votes.","Annual meeting held June 12, 2025; 56.7% of outstanding shares voted, quorum present."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":2477451958.306547,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":160100,"accession_number":"0001104659-25-052719","cik":1813814,"company_name":"Definium Therapeutics, Inc.","ticker":"DFTX","form_type":"8-K","filed_at":"2025-05-27T23:59:59+00:00","items":["5.02","7.01","9.01"],"status":"ready","headline":"MindMed appoints Brandi Roberts as CFO effective June 2, 2025; inducement awards granted","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Roberts previously CFO of Longboard Pharmaceuticals, led IPO and $2.6B Lundbeck acquisition.","Base salary $495,000; eligible for annual cash bonus up to 40% of base salary.","Inducement awards: option for 500,000 shares (4-year vest) and 125,000 PSUs (3-year vest, 0-200% payout).","Roberts replaces Carrie Liao as principal financial and accounting officer effective June 2."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":2477451958.306547,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":160099,"accession_number":"0000950170-25-066374","cik":1813814,"company_name":"Definium Therapeutics, Inc.","ticker":"DFTX","form_type":"8-K","filed_at":"2025-05-08T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"MindMed reports Q1 cash $245.5M; Phase 3 trials on track for 2026 topline data","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Cash and investments $245.5M at March 31, 2025; runway into 2027 and at least 12 months beyond first Phase 3 readout.","Dosed first patient in Phase 3 Emerge study of MM120 ODT for MDD; topline data expected 2H 2026.","Enrollment on track in Phase 3 Voyage and Panorama studies for GAD; topline data 1H 2026 (Voyage) and 2H 2026 (Panorama).","Amended K2 HealthVentures loan: up to $120M available, received ~$17.8M net cash, interest-only period extended through May 1, 2027."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.35,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2025-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":2477451958.306547,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":160098,"accession_number":"0001104659-25-036841","cik":1813814,"company_name":"Definium Therapeutics, Inc.","ticker":"DFTX","form_type":"8-K","filed_at":"2025-04-21T23:59:59+00:00","items":["1.01","2.03","3.02","9.01"],"status":"ready","headline":"MindMed amends credit facility, gets $42M new term loan; total capacity up to $120M","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Restated credit facility provides up to $120M in term loans; $42M funded immediately to refinance existing debt.","Interest rate lowered to greater of 10.25% or Prime+2.75%; maturity extended to April 1, 2029.","Lenders may convert up to $7M of debt into common shares at $4.01-$9.00 per share.","Additional $28M tranche available upon clinical/regulatory milestones; $50M discretionary tranche.","Minimum liquidity covenant effective July 1, 2026 if milestones missed; waived if market cap >$500M."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":2477451958.306547,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":160097,"accession_number":"0000950170-25-053953","cik":1813814,"company_name":"Definium Therapeutics, Inc.","ticker":"DFTX","form_type":"8-K","filed_at":"2025-04-15T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"MindMed doses first patient in Phase 3 Emerge study of MM120 ODT for MDD","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["First patient dosed in Phase 3 Emerge study evaluating MM120 ODT 100 µg vs placebo in major depressive disorder.","Primary endpoint: change from baseline in MADRS score at Week 6; ~140 participants expected in U.S.","Topline data from the 12-week double-blind period anticipated in second half of 2026.","Emerge is the third Phase 3 study of MM120 ODT; Voyage and Panorama studies in GAD are already underway.","Phase 2b GAD study showed clinically and statistically significant MADRS improvements after single 100 µg dose."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":2477451958.306547,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":178420,"accession_number":"0000950170-25-034175","cik":1813814,"company_name":"Definium Therapeutics, Inc.","ticker":"DFTX","form_type":"8-K","filed_at":"2025-03-06T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"MindMed reports $273.7M cash, advances MM120 Phase 3 trials in GAD and MDD","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Cash and equivalents $273.7M at Dec 31, 2024 vs $99.7M a year ago; raised ~$250M in 2024.","Q4 2024 R&D expense $21.8M (from $11.5M); full-year $65.3M (from $52.1M).","Phase 3 Voyage (GAD) dosing initiated; topline data expected 1H 2026.","Phase 3 Panorama (GAD) initiated Q1 2025; data expected 2H 2026.","On track to start Phase 3 Emerge (MDD) 1H 2025; topline data 2H 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":2477451958.306547,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":178419,"accession_number":"0000950170-25-010802","cik":1813814,"company_name":"Definium Therapeutics, Inc.","ticker":"DFTX","form_type":"8-K","filed_at":"2025-01-30T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"MindMed doses first patient in Phase 3 Panorama study of MM120 for GAD; data H2 2026","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["First patient dosed in Panorama, second Phase 3 study of MM120 ODT (LSD) for generalized anxiety disorder.","Study will enroll ~250 participants at US/European sites; randomized 2:1:2 to 100µg, 50µg, or placebo.","Primary endpoint: change from baseline in HAM-A at Week 12 for MM120 ODT 100µg vs placebo.","Topline data from 12-week double-blind period anticipated in second half of 2026.","Builds on positive Phase 2b results; first Phase 3 study Voyage also recently launched."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":2477451958.306547,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":178418,"accession_number":"0001104659-25-002868","cik":1813814,"company_name":"Definium Therapeutics, Inc.","ticker":"DFTX","form_type":"8-K","filed_at":"2025-01-13T23:59:59+00:00","items":["5.02","8.01","9.01"],"status":"ready","headline":"MindMed terminates Executive President Miri Halperin Wernli without cause, effective Feb 28, 2025","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Employment terminated without cause; effective February 28, 2025.","Reason cited: centralizing management team in the United States for strategic alignment.","No replacement announced; CEO Robert Barrow remains.","Updated corporate presentation filed as Exhibit 99.1 on January 13, 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":2477451958.306547,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":195076,"accession_number":"0000950170-24-136386","cik":1813814,"company_name":"Definium Therapeutics, Inc.","ticker":"DFTX","form_type":"8-K","filed_at":"2024-12-16T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"MindMed doses first patient in Phase 3 Voyage study of MM120 for GAD","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["First-ever Phase 3 study of lysergide D-tartrate (LSD) for GAD; primary endpoint HAM-A change at week 12 vs placebo.","Voyage study to enroll ~200 participants in US; topline data from 12-week double-blind period expected H1 2026.","Builds on positive Phase 2b study results presented at APA Annual Meeting in May 2024; second Phase 3 Panorama study on track for H1 2025.","MM120 ODT is a pharmaceutically optimized form of LSD; study includes 52-week duration with 40-week open-label extension."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":2477451958.306547,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":195075,"accession_number":"0000950170-24-123366","cik":1813814,"company_name":"Definium Therapeutics, Inc.","ticker":"DFTX","form_type":"8-K","filed_at":"2024-11-07T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"MindMed Q3 net loss $13.7M; cash $295.3M; Phase 3 Voyage on track for Q4 2024","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $13.7M vs $17.9M a year ago; R&D expenses $17.2M (up $4.0M YoY) on MM120/MM402 programs.","Cash and equivalents $295.3M as of Sep 30, 2024; expected to fund operations into 2027.","Phase 3 Voyage study of MM120 ODT in GAD to start Q4 2024; 12-week topline data expected H1 2026.","Phase 3 Panorama (GAD) and Phase 3 Emerge (MDD) studies on track to initiate in H1 2025.","Completed Phase 1 study of MM402 (R(-)-MDMA) for Autism Spectrum Disorder in October 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.12,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2024-Q3","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":2477451958.306547,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":195074,"accession_number":"0001104659-24-109539","cik":1813814,"company_name":"Definium Therapeutics, Inc.","ticker":"DFTX","form_type":"8-K","filed_at":"2024-10-17T23:59:59+00:00","items":["1.01","3.02","8.01","9.01"],"status":"ready","headline":"MindMed exchanges 8M common shares for pre-funded warrants at $0.001 exercise price","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Exchanged 8,000,000 common shares held by Commodore Capital and Deep Track Biotechnology for pre-funded warrants to purchase 8,000,000 common shares at $0.001 each.","Warrants are exercisable immediately, no expiration, subject to 9.99% beneficial ownership limitation (can be increased to 19.99% with 61 days notice).","Company and holders amended Registration Rights Agreement to register resale of warrant shares; prospectus supplement filed with SEC.","Exchange structured as exempt transaction under Section 3(a)(9) of the Securities Act; no commissions paid.","Holders originally acquired the shares in a March 2024 private placement of 12.5M shares."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":2477451958.306547,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":211358,"accession_number":"0000950170-24-095749","cik":1813814,"company_name":"Definium Therapeutics, Inc.","ticker":"DFTX","form_type":"8-K","filed_at":"2024-08-13T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"MindMed Q2 net loss narrows to $5.9M; cash at $243M to fund Phase 3 in GAD","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Net loss of $5.9 million, down from $29.1 million in Q2 2023, primarily due to warrant fair value changes.","Cash and equivalents of $243.1 million as of June 30, 2024; plus ~$70M net from July 2024 offering, extending runway into 2027.","Completed end-of-Phase 2 meeting with FDA; first Phase 3 trial (Voyage) for MM120 ODT in GAD to start H2 2024 with topline in H1 2026.","Expanding pipeline: registrational study (Emerge) for MM120 ODT in MDD planned for H1 2025, topline H2 2026.","New USPTO patent issued covering MM120 ODT formulation and method of treatment, extending IP protection through 2041."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":2477451958.306547,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":211357,"accession_number":"0001104659-24-088108","cik":1813814,"company_name":"Definium Therapeutics, Inc.","ticker":"DFTX","form_type":"8-K","filed_at":"2024-08-12T23:59:59+00:00","items":["1.01","2.02","8.01","9.01"],"status":"ready","headline":"MindMed prices $75M public offering of common shares and pre-funded warrants; cash position $243.1M","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Underwritten public offering of 9,285,511 common shares at $7.00/share and 1,428,775 pre-funded warrants at $6.999/warrant.","Gross proceeds of ~$75M; net proceeds of ~$70M after underwriting discounts and expenses.","Preliminary cash and cash equivalents of ~$243.1M as of June 30, 2024, disclosed in prospectus supplement.","Offering expected to close on August 12, 2024; net proceeds to fund R&D and working capital.","Leerink Partners and Evercore ISI acting as joint bookrunning managers; RBC and Oppenheimer as lead managers."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":2477451958.306547,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":229984,"accession_number":"0001104659-24-076037","cik":1813814,"company_name":"Definium Therapeutics, Inc.","ticker":"DFTX","form_type":"8-K","filed_at":"2024-06-28T23:59:59+00:00","items":["1.01","8.01","9.01"],"status":"ready","headline":"MindMed enters $150M ATM equity program with Leerink Partners, terminates prior ATM","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["New at-the-market sales agreement with Leerink Partners LLC authorizes sale of up to $150M in common shares.","Agent commission capped at 3.0% of gross proceeds; company has no obligation to sell shares.","Prior Controlled Equity Offering agreement with Cantor Fitzgerald and Oppenheimer terminated on May 28, 2024.","Company may suspend or terminate the new ATM facility at any time."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":2477451958.306547,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":229983,"accession_number":"0000950170-24-075317","cik":1813814,"company_name":"Definium Therapeutics, Inc.","ticker":"DFTX","form_type":"8-K","filed_at":"2024-06-20T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"MindMed reaches alignment with FDA on Phase 3 plan for MM120 in GAD","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Constructive End-of-Phase 2 meeting with FDA; aligned on Phase 3 requirements for MM120 (LSD D-tartrate) in generalized anxiety disorder.","Phase 3 program initiation remains on schedule for second half of 2024.","Phase 2b MMED008 trial results: MM120 100 µg cohort showed 65% clinical response rate and 48% remission rate on HAM-A at Week 12.","Last new FDA approval for GAD was in 2007; no robust treatment options have emerged since."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":2477451958.306547,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":229982,"accession_number":"0000950170-24-071953","cik":1813814,"company_name":"Definium Therapeutics, Inc.","ticker":"DFTX","form_type":"8-K","filed_at":"2024-06-11T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"MindMed shareholders elect directors, approve auditor and employee share purchase plan","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Six director nominees elected with votes for ranging from 18.1M to 23.7M; broker non-votes 13.8M.","Appointment of KPMG LLP as auditor approved: 36.8M for, 0.8M withheld.","2024 Employee Share Purchase Plan approved: 23.4M for, 0.3M against, 0.2M abstain, 13.8M broker non-votes.","Quorum of 37.6M shares (52.4% of 71.9M outstanding) present at June 10 meeting."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.15,"market_cap_usd":2477451958.306547,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":229981,"accession_number":"0000950170-24-055649","cik":1813814,"company_name":"Definium Therapeutics, Inc.","ticker":"DFTX","form_type":"8-K","filed_at":"2024-05-08T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"MindMed reports Q1 net loss $54.4M; MM120 GAD trial hits key endpoint, FDA Breakthrough Therapy","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $54.4M Q1'24 (vs $24.8M); includes $27.7M warrant fair value change. R&D $11.7M, G&A $10.5M.","Cash $252.3M at Mar 31 (vs $99.7M Dec'23). Expects funding into 2026.","Phase 2b MM120 GAD: 7.7-pt HAM-A improvement vs placebo (p<0.003), 65% response, 48% remission at Week 12.","FDA Breakthrough Therapy for MM120 in GAD. Phase 3 initiation planned H2 2024.","CFO Schond Greenway departed May 3. Executive search for new CFO underway."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.14,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2024-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":2477451958.306547,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":229980,"accession_number":"0000950170-24-039484","cik":1813814,"company_name":"Definium Therapeutics, Inc.","ticker":"DFTX","form_type":"8-K","filed_at":"2024-04-01T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"MindMed voluntarily delists from Cboe Canada effective April 10, 2024; continues Nasdaq listing","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Voluntary delisting from Cboe Canada at market close on April 10, 2024; Cboe Canada accepted notice.","Common shares to continue trading on Nasdaq under symbol MNMD; ~95% of trading volume already on Nasdaq.","Company cites insufficient Cboe Canada volume to justify dual listing costs; savings redirected to shareholder initiatives.","Board approved delisting; no shareholder approval required as alternative market exists on Nasdaq."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.25,"market_cap_usd":2477451958.306547,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":248431,"accession_number":"0001193125-24-064380","cik":1813814,"company_name":"Definium Therapeutics, Inc.","ticker":"DFTX","form_type":"8-K","filed_at":"2024-03-11T23:59:59+00:00","items":["1.01","3.02","8.01","9.01"],"status":"ready","headline":"MindMed prices $175M combined offering of common shares at $6.00 each","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Underwritten offering of 16,666,667 common shares at $6.00 per share with net proceeds of ~$93.8M.","Concurrent private placement of 12,500,000 common shares at $6.00 per share to Deep Track Capital and Commodore Capital, net proceeds ~$70.3M.","Combined gross proceeds expected to be ~$175M; closing expected on March 11, 2024.","Proceeds will be used for R&D of product candidates, working capital, and general corporate purposes."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.9,"calibrated_materiality_score":0.9,"market_cap_usd":2477451958.306547,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":248430,"accession_number":"0001193125-24-061522","cik":1813814,"company_name":"Definium Therapeutics, Inc.","ticker":"DFTX","form_type":"8-K","filed_at":"2024-03-07T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"MindMed reports Phase 2b topline data for MM120 in GAD; gets FDA Breakthrough Therapy Designation","summary_kind":"llm","event_type":"other_material","confidence":"medium","bullets":["Phase 2b trial of MM120 (LSD) for Generalized Anxiety Disorder: full topline data released on March 7, 2024.","FDA granted Breakthrough Therapy Designation for MM120 in GAD, accelerating development and review.","Company hosted conference call to discuss results and ODT PK bridging study data.","MM120 is a proprietary sublingual formulation of lysergide targeting anxiety disorders."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":2477451958.306547,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":248429,"accession_number":"0001193125-24-061361","cik":1813814,"company_name":"Definium Therapeutics, Inc.","ticker":"DFTX","form_type":"8-K","filed_at":"2024-03-07T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"FDA grants Breakthrough Therapy Designation to MindMed's MM120 for GAD; Phase 2b shows durable 12-week effect","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["FDA breakthrough designation for MM120 (lysergide d-tartrate) to treat generalized anxiety disorder.","Phase 2b met key secondary endpoint: MM120 100 µg showed 7.7-point HAM-A improvement vs placebo at Week 12 (p<0.003).","65% clinical response rate and 48% clinical remission rate sustained to Week 12 from a single dose.","Plans End-of-Phase 2 meeting with FDA in H1 2024, Phase 3 initiation in H2 2024.","Terminated ATM prospectus for up to $100M of common shares; no new sales until new prospectus filed."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":2477451958.306547,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":248428,"accession_number":"0000950170-24-021650","cik":1813814,"company_name":"Definium Therapeutics, Inc.","ticker":"DFTX","form_type":"8-K","filed_at":"2024-02-28T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"MindMed reports FY2023 net loss $95.7M; Phase2b MM120 shows 7.6-point HAM-A reduction for GAD","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Cash and equivalents $99.7M vs $142.1M at Dec 2022; expected to fund operations into 2026.","Net loss $95.7M vs $56.8M in 2022; R&D expenses $52.1M (up $15.9M) driven by MM120 Phase 2b trial.","Phase 2b MM120 (100 µg) achieved 7.6-point HAM-A reduction vs placebo (p<0.0004, effect size 0.88); 78% response rate.","Plans End-of-Phase 2 FDA meeting H1 2024, Phase 3 MM120 GAD program start H2 2024; March 7 investor event for 12-week data.","Initiated Phase 1 trial of MM402 (R(-)-MDMA) for ASD in Q4 2023."],"consensus_eps_estimate":null,"consensus_eps_actual":-2.44,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2023-FY","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":2477451958.306547,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":248427,"accession_number":"0000950170-24-002705","cik":1813814,"company_name":"Definium Therapeutics, Inc.","ticker":"DFTX","form_type":"8-K","filed_at":"2024-01-08T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"MindMed provides 2024 outlook; GAD Phase 2b showed 7.6-point HAM-A reduction, ADHD trial failed","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["MM-120 100µg GAD: 7.6 HAM-A reduction vs placebo (p<0.0004, effect size 0.88); 78% response, 50% remission.","ADHD Phase 2a sub-perceptual dose trial failed primary endpoint; no further development for that regimen.","End-of-Phase 2 FDA meeting H1 2024; Phase 3 initiation expected H2 2024 for MM-120 in GAD.","Full 12-week Phase 2b results for MM-120 in GAD expected by Q1 2024 end.","Phase 1 for MM-402 (R(-)-MDMA) in ASD started Q4 2023; UHB MDMA trial topline data H1 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":2477451958.306547,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":265923,"accession_number":"0001193125-23-294936","cik":1813814,"company_name":"Definium Therapeutics, Inc.","ticker":"DFTX","form_type":"8-K","filed_at":"2023-12-14T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"MindMed Phase 2b MM-120 in GAD meets primary endpoint, 7.6-point HAM-A improvement vs placebo","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["MM-120 100 µg achieved 21.3-point HAM-A reduction vs 13.7 placebo (p=0.0004, Cohen's d=0.88) at Week 4 after single dose.","Clinical response rate 78% (100/200 µg) and remission 50% (100 µg) at Week 4; CGI-S improved from 'markedly ill' to 'borderline'.","Well-tolerated with mostly mild-moderate AEs on dosing day; 97.5% completion in high-dose groups with no AE discontinuations.","Plans End-of-Phase 2 meeting with FDA in H1 2024 and initiation of Phase 3 program in H2 2024; 12-week data expected Q1 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.9,"calibrated_materiality_score":0.9,"market_cap_usd":2477451958.306547,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":265922,"accession_number":"0000950170-23-058230","cik":1813814,"company_name":"Definium Therapeutics, Inc.","ticker":"DFTX","form_type":"8-K","filed_at":"2023-11-02T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"MindMed Q3 net loss $17.9M; cash $117.7M; Phase 2b GAD topline expected Q4 2023","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Cash and cash equivalents $117.7M at Sept 30, 2023; expected to fund operations into 2026.","Net loss $17.9M in Q3 2023 vs $16.5M in Q3 2022; R&D expenses rose to $13.2M from $7.8M.","Phase 2b study of MM-120 in GAD (198 participants) topline results expected in Q4 2023.","Phase 2a proof-of-concept study of MM-120 in ADHD (53 participants) topline data expected Q1 2024.","Initiation of Phase 1 study of MM-402 for ASD expected in Q4 2023."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.85,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2023-Q3","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":2477451958.306547,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":283144,"accession_number":"0000950170-23-048432","cik":1813814,"company_name":"Definium Therapeutics, Inc.","ticker":"DFTX","form_type":"8-K/A","filed_at":"2023-09-15T23:59:59+00:00","items":[],"status":"ready","headline":"MindMed amends 8-K to correct jurisdiction to British Columbia, Canada","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["The amendment corrects a clerical error on the cover page of the August 14, 2023 8-K.","Company's jurisdiction of incorporation is British Columbia, Canada, not as previously noted.","No other changes to the original filing or its exhibits.","Original 8-K reported posting of an updated corporate presentation."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.0,"calibrated_materiality_score":0.0,"market_cap_usd":2477451958.306547,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":283143,"accession_number":"0000950170-23-048428","cik":1813814,"company_name":"Definium Therapeutics, Inc.","ticker":"DFTX","form_type":"8-K/A","filed_at":"2023-09-15T23:59:59+00:00","items":[],"status":"ready","headline":"Mind Medicine files 8-K/A to correct jurisdiction of incorporation to British Columbia","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Corrects prior 8-K cover page jurisdiction from erroneous entry to British Columbia, Canada.","Original Aug 14, 2023 8-K reported a loan agreement with K2 HealthVentures; this amendment does not alter that disclosure.","No financial, operational, or liquidity impact; purely administrative correction.","Company continues to trade on Nasdaq under symbol MNMD."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.0,"calibrated_materiality_score":0.0,"market_cap_usd":2477451958.306547,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":283147,"accession_number":"0000950170-23-042472","cik":1813814,"company_name":"Definium Therapeutics, Inc.","ticker":"DFTX","form_type":"8-K","filed_at":"2023-08-14T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"MindMed posts updated investor presentation; no specific updates disclosed in exhibit text","summary_kind":"llm","event_type":"other","confidence":"low","bullets":["Filing reports updated corporate presentation posted to website on August 14, 2023.","Exhibit 99.1 contains only a cover page and legal disclaimer; no pipeline or financial data included.","Unable to identify material changes without access to full presentation content."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.25,"market_cap_usd":2477451958.306547,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":283146,"accession_number":"0000950170-23-042086","cik":1813814,"company_name":"Definium Therapeutics, Inc.","ticker":"DFTX","form_type":"8-K","filed_at":"2023-08-14T23:59:59+00:00","items":["1.01","2.03","3.02","9.01"],"status":"ready","headline":"MindMed enters up to $50M term loan with K2 HealthVentures; first tranche of $15M funded","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Loan Agreement with K2 HealthVentures provides term loans up to $50M; initial $15M drawn on Aug 11, 2023.","Additional $20M available upon clinical/regulatory milestones; up to $15M more at lenders' discretion.","Term loan matures Aug 1, 2027; interest rate = greater of 10.95% or Prime + 2.95%.","Lenders may convert up to $4M of principal into common shares at $4.01 per share; conversion capped at 9.985% beneficial ownership.","Proceeds for working capital and general corporate purposes; loan secured by substantially all assets except IP."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":2477451958.306547,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":283145,"accession_number":"0000950170-23-038033","cik":1813814,"company_name":"Definium Therapeutics, Inc.","ticker":"DFTX","form_type":"8-K","filed_at":"2023-08-03T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"MindMed Q2 net loss $29.1M, cash $116.9M; MM-120 GAD topline readout on track for Q4 2023","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $29.1M in Q2 2023 vs $17.0M in Q2 2022; R&D spend rose to $14.8M ($9.3M prior).","Cash and equivalents $116.9M at June 30, 2023, funding operations into first half of 2025.","MM-120 Phase 2b for GAD enrollment target lowered to 180 patients; topline results expected Q4 2023.","MM-120 Phase 2a for ADHD over 80% enrolled; topline readout expected Q4 2023 / Q1 2024.","Exclusive license agreement with Catalent for Zydis ODT formulation of MM-120 for pivotal trials."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.41,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2023-Q2","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":2477451958.306547,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":283142,"accession_number":"0000950170-23-034489","cik":1813814,"company_name":"Definium Therapeutics, Inc.","ticker":"DFTX","form_type":"8-K/A","filed_at":"2023-07-25T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"MindMed 2023 annual meeting: company slate elected, FCM nominees defeated","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Final voting results certified July 25, 2023; unchanged from preliminary results of June 27.","All six company board nominees elected (e.g., Robert Barrow 8.15M for vs 6.26M withheld).","All four FCM MM Holdings nominees failed; each had more withheld votes (e.g., Dr. Scott Freeman 6.02M for, 7.78M withheld).","KPMG LLP reappointed as auditor (14.86M for, 0.39M against, 1.08M abstain).","Quorum 42.3% of 38.59M outstanding shares; meeting held June 21."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.3,"calibrated_materiality_score":0.15,"market_cap_usd":2477451958.306547,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":302544,"accession_number":"0000950170-23-030195","cik":1813814,"company_name":"Definium Therapeutics, Inc.","ticker":"DFTX","form_type":"8-K","filed_at":"2023-06-27T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"MindMed annual meeting elects six board nominees; FCM MM Holdings challenges preliminary vote results","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Six company-nominated directors elected: Barrow, Bruhn, Crystal, Gryska, Krebs, Vallone.","FCM MM Holdings nominees Freeman, Farzaneh, Jain, Wodka failed to be elected; FCM challenging results.","KPMG LLP re-appointed as auditor with 14.86M votes for, 0.39M against, 1.08M abstain.","Company states it does not expect FCM challenge to affect outcome or quorum."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.15,"market_cap_usd":2477451958.306547,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":302543,"accession_number":"0000950170-23-028954","cik":1813814,"company_name":"Definium Therapeutics, Inc.","ticker":"DFTX","form_type":"8-K","filed_at":"2023-06-20T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"MindMed holds Analyst Day focused on MM-120 for GAD; no specific data disclosed","summary_kind":"llm","event_type":"other_material","confidence":"low","bullets":["Analyst Day held June 20, 2023 in New York, NY.","Presentation centered on MM-120 program for generalized anxiety disorder (GAD).","Exhibit 99.1 filed but contains only cover page; substantive slides not included.","No clinical results, financial guidance, or milestones announced in the filing."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.2,"market_cap_usd":2477451958.306547,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":302542,"accession_number":"0000950170-23-028678","cik":1813814,"company_name":"Definium Therapeutics, Inc.","ticker":"DFTX","form_type":"8-K","filed_at":"2023-06-16T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"MindMed annual meeting adjourned; potential Nasdaq delisting risk from quorum issue","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["2023 annual general meeting on June 15 failed due to lack of 33 1/3% quorum; reconvened for June 21 at 10 a.m. ET.","Articles allow meeting to proceed with whatever persons present if quorum not met within 30 minutes of reconvened meeting.","Nasdaq may issue non-compliance letter if less than 33 1/3% present; company has 45 days to submit plan, possible 180-day extension.","Potential delisting would negatively impact liquidity and market price; company believes it can regain compliance but no assurance."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":2477451958.306547,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":302541,"accession_number":"0000950170-23-028341","cik":1813814,"company_name":"Definium Therapeutics, Inc.","ticker":"DFTX","form_type":"8-K","filed_at":"2023-06-15T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"MindMed adjourns annual meeting due to lack of quorum; accuses FCM of deliberate obstruction","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Annual meeting on June 15, 2023 adjourned without business due to absence of required 33⅓% quorum.","Reconvened meeting set for June 21, 2023 at 10:00 a.m. ET; virtual format unchanged.","Company alleges FCM MM Holdings deliberately acted to prevent quorum and shareholder voting.","If quorum still absent at reconvened meeting, attendees present will constitute quorum per Articles.","New proxy deadline June 19, 2023; company urges vote FOR all six Board nominees on WHITE card."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":2477451958.306547,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":"2023-06-15T23:59:59+00:00|302541"}